Pharmaceuticals - Austria

Austria

The revenue in the Pharmaceuticals market in Austria is projected to reach US$3.61bn in 2024.
The largest market within the pharmaceuticals industry is Oncology Drugs, with a projected market volume of US$0.69bn in 2024.
It is expected that the revenue will experience an annual growth rate (CAGR 2024-2028) of 6.30%, resulting in a market volume of US$4.61bn by 2028.
In comparison to other countries worldwide, United States is expected to generate the highest revenue, amounting to US$636.90bn in 2024.
Austria's pharmaceutical market is experiencing a surge in demand for natural and homeopathic remedies.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

Austria, known for its scenic beauty and rich culture, has a thriving pharmaceutical market that caters to the needs of its citizens.

Customer preferences: The Austrian population has a high demand for over-the-counter drugs and dietary supplements. Additionally, there is an increasing trend towards natural and homeopathic remedies. The aging population in Austria has also led to a higher demand for pharmaceutical products related to chronic diseases such as diabetes, hypertension, and cancer.

Trends in the market: The Austrian pharmaceutical market has been growing steadily over the years. The market is highly regulated, and the government plays a significant role in determining the prices of drugs. The market is dominated by multinational companies, but there has been an increasing trend towards the growth of local companies. The COVID-19 pandemic has led to an increased demand for pharmaceutical products such as vaccines, antivirals, and respiratory drugs.

Local special circumstances: The Austrian government has implemented measures to regulate drug prices, making it challenging for companies to introduce new drugs at higher prices. The government also encourages the use of generic drugs, which are more affordable for the population. The country also has a well-established healthcare system that ensures that its citizens have access to quality healthcare.

Underlying macroeconomic factors: Austria has a stable economy with a high standard of living. The country has a highly skilled workforce and a well-developed infrastructure, which makes it an attractive destination for foreign investment. The government's focus on healthcare and the aging population has led to an increased demand for pharmaceutical products. The COVID-19 pandemic has also led to an increased demand for healthcare services and products, which has further boosted the pharmaceutical market in Austria.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.